Newsletter | December 10, 2020

12.10.20 -- Why Severability Should Be In Your Biosimilar Vocabulary

Featured Editorial
Industry Insights
Is Your Biologics At Risk For Protein Aggregation? Part 3

The main culprit of a failing biologics drug is usually a flawed formulation. In this article, we cover formulation components and how they may affect protein aggregation. Part three of a three-part series.

The Benefits Of Flow Cytometry In Immuno-Oncology Research

Flow cytometry introduces a powerful and versatile technology into studies, enabling in-depth analysis of cell signaling and behavior.

Standardization Is Key To Building A Successful Global Business Strategy

Standardized approaches to biomanufacturing can lower costs, improve outcomes, and alter the landscape of the global pharmaceutical market.

Novel Analytics To Improve Bioprocessing And Validation Guideline Review

This presentation highlights how innovative protein analysis technologies have been adopted for better comparability, release testing, and impurity monitoring to improve characterization and productivity.

News Headlines